Evidence map›Paper›PMID 42866365›Full record

ArticleRSC medicinal chemistry2026

Benchmarking AI-driven protocols for cyclic peptide conformer prediction and ranking.

Jovan Damjanovic, Rodrigo Ochoa

Abstract read
In one paragraph

Article in RSC medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jovan DamjanovicNovo Nordisk US R&D 33 Hayden Avenue Lexington MA 02421 USA jvdj@novonordisk.com.ORCID https://orcid.org/0000-0002-6019-4738
Rodrigo OchoaNovo Nordisk A/S Novo Nordisk Park, Måløv DK-2760 Denmark raoc@novonordisk.com.ORCID https://orcid.org/0000-0003-0734-2196

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Generative AI is being used in peptide design to optimize binders from early research stages. One notable application is with respect to cyclic peptides, wherein AI assists in modelling conformers in bound or solution states. This work benchmarks state-of-the-art protocols' ability to predict and rank conformers of cyclic peptide binders alone and in complex with their targets, using sequence or all-atom representations. The datasets consist of cyclic peptides with experimental structures available in public repositories. Various tools were included in the benchmark: HighFold, cyclic-aware AlphaFold2 as implemented in EvoBind2, CycPepDock, Boltz-1/1x, Boltz-2, and Chai-1. We found that more recent tools provide a structure prediction advantage over their AlphaFold2-based counterparts, although accurate results with both sets of tools are largely limited to protein-peptide complexes, rather than the free solution structure. In addition, using a cyclic relative positional encoding offset proved key for accurate prediction, and the natural amino acid representation was found to outperform the more general SMILES string input. We mirror prior literature findings on linear peptides by showing that even for accurate predictions, model confidence metrics poorly correlate with experimentally observed binding affinity. Lastly, we compare the performance of AI-based tools to that of physics-based simulations, showing that the latter remain the only way to account for intrinsic conformational flexibility of cyclic peptides, but that the former have a significant price/performance advantage in complex structure prediction. This study provides insights applicable to the design and optimization of cyclic peptides, contributing to advancements in peptide-based therapeutics.

Identifiers

PMID42866365
PMCPMC13656215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.